

The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis

Paolo Angelo Cortesi¹, Damiano Paolicelli², Marco Capobianco³, Paolo Cozzolino¹,
Lorenzo Giovanni Mantovani¹

¹ Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy

² Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari” Aldo Moro”, Bari, Italy

³ Department of Neurology, Regional Multiple Sclerosis Centre (CReSM), University-hospital San Luigi Gonzaga, Orbassano (TO), Italy

Supplementary Files

Treatment	Adverse Event	Annual probability	Cost (€)	Disutility	Source
Fingolimod	Urinary tract infection	0.060	64.3	0.00	[1-3]
	Back pain	0.056	46.0	-0.01	
	Upper respiratory tract infection	0.182	65.0	0.00	
	Type-2 second-degree atrioventricular block	0.002	2406	-0.06	
	Headache	0.181	14.5	-0.01	
	Progressive multifocal leukoencephalopathy	0.0001	17,771.4	-0.06	
Natalizumab	Depression	0.105	971.0	-0.07	[1-4]
	Urinary tract infection	0.111	64.3	0.00	
	Arthralgia	0.105	30.9	-0.01	
	Headache	0.239	14.5	-0.01	
	Progressive multifocal leukoencephalopathy	0.001	17,771.4	-0.06	
	Fatigue	0.16	€7.52	0.00	
Ocrelizumab	Infusion related reaction	0.21	4.49	0.00	[1-3,5]
	Upper respiratory tract infection	0.08	65.00	0.00	
	Nasopharyngitis	0.08	4.49	0.00	
	Urinary tract infection	0.06	64.26	0.00	
	Hypogammaglobulinemia	0.02	7680.29	-0.01	
	Headache	0.06	14.49	-0.01	
Alemtuzumab	Urinary tract infection	0.108	64.26	0.00	[1-5]
	Upper respiratory tract infection	0.086	65.00	0.00	
	Headache	0.254	14.49	-0.01	
	Autoimmune thyroiditis	0.074	370.70	-0.05	
	Immune trombocytopenia	0.004	13283.64	-0.05	
	Nephropathy	0.003	170.0	-0.05	

Table I. DMTs adverse events probability, costs and disutility

MS type	Direct non-medical costs and indirect costs (€ per patient-year)										Source
	EDSS										
	0	1	2	3	4	5	6	7	8	9	
RMS & SPMS	2,761	2,761	2,761	2,761	16,536	16,536	16,536	37,620	37,620	37,620	[6]

Table II. Direct non-medical costs and indirect costs associated to MS. Data are reported stratified per EDSS and expressed as € per patient-year




Figure 1. Number of patients treated with the DMTs in the 3 years of the budget impact analysis

References

1. McCool R, Wilson K, Arber M, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. *Mult Scler Relat Disord* 2019; 29: 55-61; <https://doi.org/10.1016/j.msard.2018.12.040>
2. Biogen Idec Ltd, Heron Evidence Development. Natalizumab (Tysabri®) for the Treatment of Adults with Highly Active Relapsing Remitting Multiple Sclerosis: Biogen Idec Single Technology Appraisal (STA) Submission to the National Institute for Health and Clinical Excellence. London: NICE; 2007. URL: www.nice.org.uk/guidance/TA127/documents/multiple-sclerosis-natalizumab-manufacturer-submissions-biogen-idec-uk-and-elan-pharma-international-ltd-joint-development-agreement-confidential-information-removed2 (last accessed November 2018)
3. National Institute For Health And Clinical Excellence – NICE. Alemtuzumab for treating relapsing-remitting multiple sclerosis. Technology appraisal guidance TA312. London: NICE, 2014. Available at www.nice.org.uk/guidance/ta312 (last accessed November 2018)
4. Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. *Lancet Neurol* 2017; 16: 925-33; [https://doi.org/10.1016/S1474-4422\(17\)30282-X](https://doi.org/10.1016/S1474-4422(17)30282-X)
5. Leist TP, Reder AT, Bermel R, et al., on behalf of the CHORDS Investigators. Year one interim analysis results of the Phase IIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments. ECTRIMS Online Library: 2018; 228479; P635
6. Battaglia M, Kobelt G, Ponzio M, et al.; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy. *Mult Scler* 2017; 23: 104-16; <https://doi.org/10.1177/1352458517708176>